Apollomics

Apollomics Biotech Inc. was established in 2016 as a high-tech innovation project currently supported by the state. It is a biotechnology company focused on new scientific development and services in the fields of biomedicine and ecological health. Its development goals are to improve the level of molecular medical testing in China, as well as the efficiency and accuracy of disease detection, especially promoting the popularization and application of internationally advanced mass spectrometry testing technology in newborn genetic disease screening and adult health testing. The company primarily targets the development of China’s pharmaceuticals, health, and environmental protection sectors, with huge market potential.The company has a clear positioning, utilizing top-tier testing technologies to enhance the efficiency and precision of disease detection. In particular, it promotes the widespread application of advanced testing technologies in newborn genetic disease screening and develops various biomarker tests to advance the development of precision oncology testing and treatment in China. The team is committed to developing domestically produced clinical testing reagents and disease detection services that match world-leading mass spectrometry testing technologies. The company's business model integrates independent research and development of testing reagents, production synthesis, scientific research cooperation, and testing market services. The main product developments include mass spectrometry analysis reagents for proteomics and metabolomics, and various clinical testing reagents targeting newborn genetic diseases, tumor markers, health testing, food safety, and environmental pollution. The company has independently developed new mass spectrometry testing reagents, obtained international technology patents, and possesses several standardized clinical testing reagents already in production. Apollomics has numerous partners, including Johns Hopkins University, Peking University, and listed companies within the industry.The company has been selected for Nanjing's Leading Scientific Entrepreneurship Program, gaining significant attention. It ranked highly in Jiangsu Province's Innovation and Entrepreneurship Haizhi Platform Competition and maintains close relationships with many venture capitalists. In 2018, it completed its Pre-A round of financing. Located in Nanjing, the ancient capital of six dynasties, the company benefits from being in an important base for scientific research and education and a comprehensive transportation hub in China. Situated near the Life Science and Technology Innovation Park close to the renowned Nanjing University, the company enjoys excellent natural and cultural environments suitable for long-term development. Talented individuals are welcome to join the team and witness their growth potential.